The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated Patient-Reported Outcome (PRO) tool. Panelists included experts in NTM and in PRO,...Read More
On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM) infection. At this workshop, we will convey patient experiences and preferences. Ahead of the workshop, we have published a survey to gather more information about patient preferences....Read More
WHAT IS NTM?
“NTM” is short for Nontuberculous Mycobacteria. NTM disease is a serious chronic lung illness.